You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 16, 2025

CLINICAL TRIALS PROFILE FOR PANTOPRAZOLE SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for pantoprazole sodium

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00300755 ↗ Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD) Completed Nycomed Phase 3 2006-05-01 To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
NCT00259012 ↗ Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD Completed Nycomed Phase 3 2005-11-01 The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles to determine the safety and tolerability of single and multiple doses of pantoprazole in infants aged 1 through 11 months.
NCT00259012 ↗ Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2005-11-01 The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles to determine the safety and tolerability of single and multiple doses of pantoprazole in infants aged 1 through 11 months.
NCT00141817 ↗ Study Evaluating Pantoprazole in Children With GERD Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2005-08-01 The purpose of this study is to characterize the PK profile, safety and tolerability of single and multiple doses of pantoprazole in children aged 1 through 11 years with endoscopically proven GERD.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 4 of 4 entries

Clinical Trial Conditions for pantoprazole sodium

Condition Name

7711001234567Gastroesophageal RefluxHealthyFEDUlcer Hemorrhage[disabled in preview]
Condition Name for pantoprazole sodium
Intervention Trials
Gastroesophageal Reflux 7
Healthy 7
FED 1
Ulcer Hemorrhage 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

85320012345678Gastroesophageal RefluxEsophagitis, PepticMalnutritionHemorrhage[disabled in preview]
Condition MeSH for pantoprazole sodium
Intervention Trials
Gastroesophageal Reflux 8
Esophagitis, Peptic 5
Malnutrition 3
Hemorrhage 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for pantoprazole sodium

Trials by Country

+
Trials by Country for pantoprazole sodium
Location Trials
United States 111
Canada 10
India 7
Germany 4
South Africa 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for pantoprazole sodium
Location Trials
Texas 7
Kentucky 6
New York 5
Illinois 5
Florida 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for pantoprazole sodium

Clinical Trial Phase

16.7%66.7%8.3%8.3%012345678Phase 4Phase 3Phase 2[disabled in preview]
Clinical Trial Phase for pantoprazole sodium
Clinical Trial Phase Trials
Phase 4 2
Phase 3 8
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

91.3%0-20246810121416182022CompletedNot yet recruitingUnknown status[disabled in preview]
Clinical Trial Status for pantoprazole sodium
Clinical Trial Phase Trials
Completed 21
Not yet recruiting 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for pantoprazole sodium

Sponsor Name

trials01234567Wyeth is now a wholly owned subsidiary of PfizerNycomedTeva Pharmaceuticals USA[disabled in preview]
Sponsor Name for pantoprazole sodium
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 7
Nycomed 2
Teva Pharmaceuticals USA 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

75.9%24.1%0-2024681012141618202224IndustryOther[disabled in preview]
Sponsor Type for pantoprazole sodium
Sponsor Trials
Industry 22
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Pantoprazole Sodium: Clinical Trials, Market Analysis, and Projections

Introduction

Pantoprazole sodium, a proton pump inhibitor (PPI), is widely used for the treatment of gastroesophageal reflux disease (GERD) and other conditions involving excessive gastric acid production. Here, we will delve into the recent clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Efficacy

Recent Clinical Trials and Approvals

A recent supplemental new drug application (NDA 20988/S-070) was submitted for Protonix IV (pantoprazole sodium) for the short-term intravenous (IV) treatment of GERD associated with a history of erosive esophagitis (EE) in pediatric patients aged 3 months and older. This approval was based on extrapolation of efficacy data from adequate and well-controlled trials in adults and pediatric patients, along with pharmacokinetic (PK) and safety studies in pediatric subjects[1].

Safety and Adverse Reactions

Clinical trials have shown that the safety profile of pantoprazole sodium is generally consistent across different age groups. However, adverse reactions such as headache, diarrhea, nausea, abdominal pain, and vomiting have been reported. Specific to IV administration, thrombophlebitis has been identified as a unique adverse reaction[4].

Long-term Safety Concerns

Long-term use of pantoprazole sodium has been associated with several safety concerns, including an increased risk of osteoporosis-related fractures, acute interstitial nephritis, Clostridium difficile-associated diarrhea, and hypomagnesemia. Additionally, there have been reports of cutaneous and systemic lupus erythematosus, which necessitate discontinuation of the drug and specialist evaluation[3][4].

Market Analysis

Market Size and Growth

The pantoprazole sodium market is projected to achieve significant growth over the forecast period. According to FutureWise Research, the market is expected to record a remarkable growth rate, driven by increasing demand for effective treatments for GERD and other gastroenterological conditions. The market segmentation includes various product types (delayed-release tablets, injections, and enteric-coated capsules), applications (gastroenterology and hepatology), and geographical regions[2].

Geographical Augmentation

The market for pantoprazole sodium is diverse and spread across various regions. North America, Europe, Latin America, and the Asia Pacific are key markets, each with their own historical market size analysis and forecasted growth. For instance, the U.S., Canada, and Mexico in North America, and Germany, the U.K., and France in Europe, are significant contributors to the global market[2].

Competitive Landscape

The competitive landscape of the pantoprazole sodium market includes several key players. The market is characterized by a mix of branded and generic products, with companies focusing on brand protection and exploring untapped opportunities in emerging regions. The report by FutureWise Research provides an in-depth analysis of the market share, SWOT analysis, and geographical augmentation of these players[2].

Market Projections

Forecasted Growth

The pantoprazole sodium market is anticipated to grow at a steady rate, driven by the increasing prevalence of GERD and other gastroenterological disorders. The global pantoprazole API market is expected to rise at a CAGR of 3.2% during the forecast period of 2020-2026[5].

Emerging Regions

Emerging regions, particularly in the Asia Pacific and Latin America, are expected to contribute significantly to the market growth. These regions offer untapped opportunities due to their large patient populations and growing healthcare infrastructure[2].

Regulatory Framework

The regulatory framework plays a crucial role in the market dynamics of pantoprazole sodium. The FDA approvals and safety labeling changes have a direct impact on the market. For instance, the recent approval for pediatric use has expanded the market potential for this drug[1][3].

Key Takeaways

  • Clinical Trials: Recent approvals for pediatric use and safety studies have expanded the efficacy and safety profile of pantoprazole sodium.
  • Market Growth: The market is projected to grow significantly, driven by increasing demand and emerging regions.
  • Safety Concerns: Long-term use is associated with several safety concerns, necessitating careful patient monitoring.
  • Geographical Augmentation: The market is diverse, with significant contributions from North America, Europe, Latin America, and the Asia Pacific.
  • Competitive Landscape: The market includes both branded and generic products, with a focus on brand protection and emerging market opportunities.

FAQs

What are the recent clinical trial updates for pantoprazole sodium?

Recent clinical trials have focused on the approval of pantoprazole sodium for pediatric patients aged 3 months and older for the short-term IV treatment of GERD associated with EE. These trials have established the safety and efficacy through extrapolation from adult and pediatric studies[1].

What are the common adverse reactions associated with pantoprazole sodium?

Common adverse reactions include headache, diarrhea, nausea, abdominal pain, and vomiting. Thrombophlebitis is a unique adverse reaction associated with IV administration[4].

What is the projected market growth for pantoprazole sodium?

The market is expected to grow at a CAGR of 3.2% during the forecast period, driven by increasing demand and emerging market opportunities[5].

Which regions are expected to contribute significantly to the market growth?

Emerging regions such as the Asia Pacific and Latin America are expected to contribute significantly to the market growth due to their large patient populations and growing healthcare infrastructure[2].

What are the long-term safety concerns associated with pantoprazole sodium?

Long-term use is associated with increased risks of osteoporosis-related fractures, acute interstitial nephritis, Clostridium difficile-associated diarrhea, and hypomagnesemia. Additionally, there are reports of cutaneous and systemic lupus erythematosus[3][4].

Sources

  1. FDA: NDA 20988/S-070 Protonix IV (Pantoprazole Sodium) Integrated Review Template, version 4.0 (11/1/23)[1].
  2. FutureWise Research: Pantoprazole Sodium Market Overview[2].
  3. FDA: 209463Orig1s000 | FDA Clinical Review Marjorie F. Dannis, M.D. NDA 209,463 Pantoprazole sodium[3].
  4. FDA: pantoprazole sodium in 0.9% sodium chloride injection[4].
  5. Global Market Estimates: Global Pantoprazole API Market Analysis | Size & Forecasts[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.